When should an adult with chronic non‑cancer pain be converted from short‑acting (immediate‑release) opioids to long‑acting (extended‑release) opioids?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

When to Convert from Short-Acting to Long-Acting Opioids in Chronic Non-Cancer Pain

Convert to long-acting opioids only when chronic pain is controlled on stable doses of short-acting opioids taken consistently around-the-clock, typically requiring multiple daily doses. This conversion should never be the initial approach to opioid therapy.

Initial Opioid Therapy: Always Start Short-Acting

Start all patients with immediate-release (short-acting) opioids, never with extended-release/long-acting (ER/LA) formulations 1, 2. This applies to acute, subacute, and chronic pain. The 2022 CDC guidelines explicitly state that ER/LA opioids should not be used to initiate opioid treatment for chronic pain 2.

Key Principle

Long-acting opioids are reserved for severe, continuous pain and should only be considered after establishing opioid tolerance and stable dosing with immediate-release formulations 2.

Specific Criteria for Conversion

Convert to long-acting opioids when ALL of the following conditions are met:

1. Pain Pattern Requirements

  • Continuous, persistent pain (not intermittent)
  • Pain present throughout most of the day requiring regular dosing 3
  • Not for "as-needed" or breakthrough pain only 2

2. Dosing Stability Achieved

  • Patient has been on stable doses of short-acting opioids
  • Consistent around-the-clock administration established 3
  • Pain adequately controlled at current short-acting dose
  • FDA guidance suggests at least 1 week of consistent immediate-release opioid use at certain dosages before considering ER/LA conversion 2

3. Functional Goals Met

  • Patient demonstrates acceptable comfort and function on current regimen 4
  • 24-hour opioid requirement is stable and predictable 3

The Conversion Process

Step-by-Step Algorithm:

  1. Calculate total 24-hour opioid dose from all short-acting opioid sources taken in the previous day 3

  2. Determine equianalgesic dose of the chosen long-acting formulation using conversion tables

  3. Reduce the calculated dose by 25-50% to account for incomplete cross-tolerance between formulations 3

  4. Divide the total daily dose appropriately:

    • Every 12 hours for most extended-release oral formulations
    • Every 72 hours for transdermal fentanyl patches 3
  5. Prescribe breakthrough medication: Provide short-acting opioids at 10-20% of the total 24-hour dose for rescue/breakthrough pain 3

Critical Caveats and Pitfalls

What NOT to Do:

  • Never initiate opioid therapy with ER/LA formulations 1, 2
  • Never prescribe ER/LA opioids for intermittent or as-needed use 2
  • Avoid methadone as first-choice ER/LA opioid due to complex pharmacokinetics, QT prolongation risk, and need for specialized monitoring 1, 2
  • Exercise extreme caution with transdermal fentanyl - only prescribe if thoroughly familiar with its unique dosing and absorption properties 1, 2

Special Populations Requiring Extra Caution:

  • Renal or hepatic dysfunction: Consider longer dosing intervals due to decreased drug clearance and risk of toxic accumulation 2
  • Older adults: Assess for cognitive limitations that might interfere with medication management 1

Ongoing Management After Conversion

Monitoring Requirements:

  • Continue short-acting opioids for breakthrough pain (same opioid when possible) 3
  • If patient persistently needs rescue doses, increase the ER/LA dose accordingly 3
  • Reassess at each contact to ensure treatment goals for comfort and function are met 4

Dose Escalation Triggers:

Increase ER/LA dose when:

  • Patient consistently requires multiple breakthrough doses daily
  • Pain relief inadequate at peak effect of ER/LA medication
  • Pain returns at end of dosing interval 3

Context: Chronic Non-Cancer Pain Specifics

While the provided evidence primarily addresses cancer pain [3-4,3-3], the principles apply to chronic non-cancer pain with additional restrictions. The 2022 CDC guidelines emphasize that for chronic non-cancer pain, the threshold for using ER/LA opioids should be even higher, with careful justification required 2. The emergency medicine guideline explicitly states that long-acting opioids are indicated for chronic pain management, not acute pain, and should never be used in emergency settings for new-onset pain 5.

The fundamental principle remains: establish efficacy and stable dosing with immediate-release opioids first, then convert to long-acting formulations only for continuous pain requiring around-the-clock coverage.

References

Guideline

adult cancer pain.

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

Guideline

adult cancer pain, version 2.2025, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.